PriceTargets.com logo

Connect Biopharma - CNTB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.67
  • Forecasted Upside: 241.21%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$2.54 As of 12/4/2025 05:00 PM ET
▼ -0.11 (-4.15%)

This chart shows the closing price for CNTB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Connect Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNTB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNTB

Analyst Price Target is $8.67
▲ +241.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Connect Biopharma in the last 3 months. The average price target is $8.67, with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 241.21% upside from the last price of $2.54.

This chart shows the closing price for CNTB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Connect Biopharma. This rating has held steady since September 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Lake Street CapitalInitiated CoverageBuy$9.00
12/1/2025Lake Street CapitalInitiated CoverageBuy$9.00
11/13/2025BTIG ResearchReiterated RatingBuy ➝ Buy$10.00
10/31/2025BTIG ResearchInitiated CoverageBuy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$7.00
7/22/2025Northland CapmkUpgradeStrong-Buy
6/12/2025HC WainwrightInitiated CoverageBuy ➝ Buy$7.00
3/31/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
9/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
6/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/17/2024HC WainwrightBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
3/4/2024HC WainwrightInitiated CoverageBuy$7.00
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$5.00
4/12/2023Leerink PartnersReiterated RatingOutperform
2/8/2023Leerink PartnersLower TargetOutperform$9.00 ➝ $7.00
6/2/2022Cantor FitzgeraldReiterated RatingOverweight
5/5/2022Piper SandlerDowngradeOverweight ➝ Neutral
4/1/2022Leerink PartnersInitiated CoverageBuy$22.00
1/6/2022Piper SandlerLower Target$31.00 ➝ $25.00
1/6/2022Leerink PartnersLower TargetOutperform$32.00 ➝ $22.00
7/2/2021CICC ResearchInitiated CoverageOutperform$27.00
4/13/2021Leerink PartnersInitiated CoverageOutperform$32.00
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$27.00
4/13/2021Piper SandlerInitiated CoverageOverweight
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Connect Biopharma logo
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Read More

Today's Range

Now: $2.54
Low: $2.50
High: $2.65

50 Day Range

MA: $1.98
Low: $1.32
High: $3.15

52 Week Range

Now: $2.54
Low: $0.51
High: $3.28

Volume

61,883 shs

Average Volume

651,222 shs

Market Capitalization

$141.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Connect Biopharma?

The following Wall Street analysts have issued research reports on Connect Biopharma in the last year: BTIG Research, HC Wainwright, Lake Street Capital, Northland Capmk, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for CNTB.

What is the current price target for Connect Biopharma?

0 Wall Street analysts have set twelve-month price targets for Connect Biopharma in the last year. Their average twelve-month price target is $8.67, suggesting a possible upside of 241.2%. BTIG Research has the highest price target set, predicting CNTB will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Connect Biopharma in the next year.
View the latest price targets for CNTB.

What is the current consensus analyst rating for Connect Biopharma?

Connect Biopharma currently has 1 sell rating, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CNTB.

What other companies compete with Connect Biopharma?

Other companies that are similar to Connect Biopharma include Fulcrum Therapeutics, Inventiva, Jade Biosciences, Monopar Therapeutics and Invivyd. Learn More about companies similar to Connect Biopharma.

How do I contact Connect Biopharma's investor relations team?

Connect Biopharma's physical mailing address is East R&D Building 3rd Floor Science and Technology Park 6 Beijing West Road, TAICANG F4, 215400. The company's listed phone number is 18587271045 and its investor relations email address is [email protected]. The official website for Connect Biopharma is www.connectbiopharm.com. Learn More about contacing Connect Biopharma investor relations.